Clinical trials: Irritable Bowel Syndrome - Diarrhoea
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
Irritable Bowel Syndrome With Diarrhea
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
- Trial name
- TARGET3 (NCT01543178)
- Testing
- open-label rifaximin, double-blind rifaximin
- Where
- 296 sites in United States, Germany and 1 more
- Volunteers
- 2,583 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Diarrhea
Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome
Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.
- Trial name
- NCT05339243
- Testing
- ES 1, HT ES1
- Where
- 8 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Irritable Bowel Syndrome
Effects of Low FODMAP Diet on Leaky Gut
The pathophysiology of Irritable bowel syndrome (IBS) is multifactorial involving complex interplay of altered intestinal permeability, mucosal immune activation, visceral hypersensitivity and gut dysbiosis.
- Trial name
- NCT04526808
- Testing
- FODMAP diet
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Deaconess Medical Center
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation
Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients
The goal of this clinical trial is to evaluate the efficacy of an automated chatbot system in improving quality of life, reducing depression and anxiety, and decreasing visceral sensitivity in patients with Irritable Bowel…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
- Trial name
- IrBiS (NCT06837064)
- Testing
- Chatbot supporting system
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Irritable Bowel Syndrome
Safety Study of Probiotics in Adults With Irritable Bowel Syndrome
Determine the safety and preliminary effectiveness of VSL#3 in adults with IBS.
- Trial name
- NCT00971711
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Irritable Bowel Syndrome
Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome
Probiotics are friendly bacteria normally present in food products like yogurt whereas irritable bowel syndrome is a longstanding functional disorder characterized by abdominal pain and altered bowel habits either diarrhea or…
- Trial name
- SBIBS (NCT00543478)
- Testing
- Saccharomyces boulardii, Methyl cellulose powder (low viscosity)
- Where
- Pakistan
- Volunteers
- 42 people
- Sponsor
- Aga Khan University
Irritable Bowel Syndrome - Diarrhoea
Effect of Food-derived Active Components on Digestive Tract Health in Adults With Irritable Bowel Syndrome
The goal of this clinical trial is to learn if Bifidobacterium. animalis subsp. Lactis A6 Strain or resveratrol to improve the symptoms of diarrhea-predominate irritable bowel syndromes (IBS-D).
- Trial name
- NCT06779214
- Testing
- Prebiotic_L, resveratrol_L, Prebiotic_M
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS)
Enabling Microbiomics- Driven Personalized Nutrition
The goal of this observational research study is to determine how diet contributes to various gastrointestinal related conditions.
- Conditions
- Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea
- Trial name
- EMPOWER (NCT06657001)
- Where
- United States
- Volunteers
- 4,001 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
SBI in Children With d-IBS
IBS is the most common diagnosis in new patients in our pediatric gastroenterology clinic, accounting for 36 % of all new patients.
- Trial name
- NCT02609529
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Irritable Bowel Syndrome
Prevalence of Intestinal Parasitic Infections in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is common medical disorder and represent a group of diseases of the gastrointestinal tract that is characterized by chronic abdominal pain , bloating , passage of mucus or straining with bowel…
- Trial name
- NCT05830370
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
Irritable Bowel Syndrome Variant of Childhood
Clinical Study of Selective Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome.
In order to seek a more precise and convenient treatment, we made a self-made precise transplant capsule that is effective against diarrhea.
- Trial name
- NCT04890405
- Testing
- Standardized FMT, Precision Flora Transplantation
- Volunteers
- 70 people
- Sponsor
- Yanling Wei
Irritable Bowel Syndrome
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome…
- Trial name
- NCT02328547
- Testing
- Fecal microbiota transplantation capsules
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Montefiore Medical Center
Irritable Bowel Syndrome, Repetitive Transcranial Magnetic Stimulation
Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea
Objective: To identify a central hub of visceral pain in IBS-D and elucidate the mechanism by which repetitive transcranial magnetic stimulation (rTMS) confers analgesic effects.
- Conditions
- Irritable Bowel Syndrome, Repetitive Transcranial Magnetic Stimulation, Chronic Visceral Pain, Functional Magnetic Resonance Imaging
- Trial name
- rTMS (NCT06409078)
- Testing
- rTMS group
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome With Diarrhea (IBS-D)
Curcumin, Vitamin D and Green Tea in IBS-D
Irritable Bowel Syndrome (IBS) is a highly prevalent condition of the gastrointestinal tract that has significant impact on sufferer's quality of life. The diarrhoea variant (IBS-D) makes up around one third of all IBS sufferers.
- Trial name
- NCT07052890
- Testing
- Curcumin, vitamin d and green tea extract
- Where
- 3 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Dr Anthony Hobson
IBS
Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea
We present the study design of a clinical trial designed to assess the clinical effects of the multispecies probiotic combination "BIO-25" in IBS-D patients.
- Trial name
- IBS-D (NCT01667627)
- Testing
- Bio-25
- Where
- Israel
- Volunteers
- 107 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Diarrhea Predominant Irritable Bowel Syndrome
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
- Trial name
- NCT01896583
- Testing
- ASP7147
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seldar Pharma, Inc.
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed
Faecal Microbiota Transplantation in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is the most common functional bowel disorder, being present in approximately 10% of adult Europoid population. The etiology of IBS is elusive.
- Trial name
- MISCEAT (NCT04899869)
- Testing
- Faecal microbiota transplantation with active study microbiota first, Faecal microbiota transplantation with inactive autoclaved study microbiota first, Faecal microbiota transplantation with inactive autoclaved study microbiota only
- Where
- Czechia
- Volunteers
- 61 people
- Sponsor
- Thomayer University Hospital